Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets

Fig. 1

Rate of ERBB2 and ERBB3 mutations and their spatial distribution on HER2/3 in ILC and IDC. ERBB2mut were found to be a enriched in ILC (yellow bar) vs. IDC (blue bar) and b clustered in the tyrosine kinase domain of HER2; c ERBB3mut occurred at lower frequency, with the high-frequency outlier in IDC coding for known oncogenic HER3 kinase domain alteration E928G (N = 6). Y-axes show the number of cases harboring at least one ERBB2/3 mutation at a specific amino acid (aa) of HER2/3, shown along the x-axes. Yellow-filled circles indicate oncERBB2mut. Extracellular domains of HER2/3: Receptor L, Furin-like and Growth Factor Receptor IV; intracellular: tyrosine protein kinase. *p < 0.001; n/s = not significant

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us